News

Article

Study finds cannabis users face higher risk of Thyroid Eye Disease

Author(s):

Key Takeaways

  • Cannabis users with autoimmune hyperthyroidism have a higher risk of developing TED outcomes, particularly within the first year.
  • The study utilized a cohort design with data from 36,186 patients, including cannabis users, cigarette smokers, and controls.
SHOW MORE

The authors noted that while an association between cigarette smoking and TED has been well established, an association between TED and cannabis use has not been determined.

(Image Credit: AdobeStock/Aleksej)

(Image Credit: AdobeStock/Aleksej)

Amanda Zong, BS, and Anne Barmettler, MD, from the Department of Ophthalmology and Visual Sciences, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, reported that cannabis users had a significantly increased risk for thyroid eye disease (TED) outcomes.1 They published their study in Ophthalmic Plastic and Reconstructive Surgery.

They conducted this study to identify an association between TED and cannabis use in patients who were diagnosed with autoimmune hyperthyroidism. The investigators pointed out that while the association between cigarette smoking and TED has been well established, an association between TED and cannabis use has not been determined.

Study design and results

The researchers conducted a cohort study that included patient data in TriNetX, an electronic health record platform, for patients with autoimmune hyperthyroidism over a 20-year period.

The primary study outcomes were TED presentation, ie, exophthalmos, eyelid retraction, eyelid edema, orbital edema, strabismus, and optic neuropathy, and treatments (teprotumumab, Tepezza, Horizon Therapeutics), methylprednisolone, tarsorrhaphy, and orbital decompression, among patients who used cannabis, those who smoked cigarettes, and control patients.

The relative risks among the cohorts were calculated for each outcome in 6-month and 1- and 2-year intervals after autoimmune hyperthyroidism was diagnosed.

The investigators identified 36,186 patients with autoimmune hyperthyroidism, of whom 783 used cannabis, 17,310 used nicotine, and 18,093 were control patients who used neither substance.

“Compared with control patients, cannabis users were more likely to be younger, male, Black/African American, and have anxiety or depression. After propensity matching, cannabis users were 1.9 times more likely to develop exophthalmos (p = 0.03) and 1.6 times more likely to develop any TED presentation (p = 0.049) during the 1-year interval. The differences were not significant in the 2-year interval,” Zong and Barmettler reported.

The authors concluded that patients with autoimmune hyperthyroidism who used cannabis had a significantly increased risk for TED outcomes in the 1-year interval. They advised that further research is needed regarding the management of TED.

Reference:
  1. Zong AM, Barmettler A. Effect of cannabis usage on thyroid eye disease. Ophthal Plast Reconstr Surg 2025;41:179-185. doi: 10.1097/IOP.0000000000002770

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.